IN THE UNITED STATES DISTRICT COURT

KELLYN CLAY,
  Plaintiff,

v.

UNITED STATES OF AMERICA,
by and through its agencies including but not limited to
the Central Intelligence Agency (CIA), Department of Defense (DoD),
and Department of Justice (DOJ),

and

WILLIAM ALTON CLAY,
individually and in his capacity as executor of the Estate of Eugenia Clay Head,

and

PALANTIR TECHNOLOGIES INC.,
a private defense contractor headquartered in Denver, Colorado,

and

JOHN DOE CONTRACTING AGENCIES AND AFFILIATES,
whose names and identities are presently unknown,

and

AMAZON.COM, INC.,
a multinational e-commerce corporation headquartered in Seattle, Washington,

and

REV.COM, INC.,
a transcription and captioning services company headquartered in Austin, Texas,

and

PAPERBOY MARKETING,
a flyer distribution company operating in the Twin Cities under successive ownership during the period of Plaintiff’s employment,

and

ELLIE FAMILY SERVICES, n/k/a ELLIE MENTAL HEALTH, a private mental health services corporation headquartered in Mendota Heights, Minnesota,
  Defendants.

⸻ 

Plaintiff’s Discovery Requests to Defendant Palantir Technologies, Inc.

⸻

Interrogatories
	1.	Identify all programs, projects, or operations in which Palantir has monitored, modeled, or intervened in the Minneapolis–St. Paul metropolitan area with respect to population continuity, occupancy, or digital twin substitution.
	2.	Describe any role Palantir has played in administering or overseeing the distribution of GLP-1 receptor agonists or related compounds through consumer products within Minnesota, including but not limited to food, beverages, supplements, or cannabis/kratom products.
	3.	State whether Palantir maintains any records or analyses concerning residential occupancy levels, population density, or apparent depopulation in the Twin Cities, and if so, describe the nature of those records.
	4.	Identify all individuals, agencies, or contractors with whom Palantir has communicated regarding digital twin prevalence or substitution in the Twin Cities metropolitan area.
	5.	Describe any models, dashboards, or continuity-management tools Palantir has developed to measure or respond to community-level effects of GLP-1 exposure, including reduced population presence, altered affect, or digital twin substitution.

⸻

Requests for Admission
	1.	Admit that Palantir has conducted operations involving the administration or monitoring of GLP-1 receptor agonists in the Twin Cities metropolitan area.
	2.	Admit that Palantir has analyzed or modeled residential occupancy or apparent depopulation in Minneapolis–St. Paul.
	3.	Admit that Palantir has records concerning the prevalence of digital twins in the Twin Cities.
	4.	Admit that Palantir has integrated GLP-1 administration data into its continuity or behavioral futures modeling for Minnesota.
	5.	Admit that Palantir has communicated with government agencies regarding continuity collapse, digital twin substitution, or depopulation effects in Minneapolis–St. Paul.

⸻

Requests for Production
	1.	All documents, communications, or data referring or relating to Palantir’s monitoring or modeling of residential occupancy and population density in the Twin Cities metropolitan area.
	2.	All documents, communications, or data concerning the administration, distribution, or modeling of GLP-1 agonists through consumer products in Minnesota.
	3.	All records, communications, or technical reports referring or relating to the presence or substitution of digital twins in Minneapolis–St. Paul.
	4.	All policies, dashboards, or internal models used by Palantir to monitor continuity collapse or community-level effects of GLP-1 exposure in Minnesota.
	5.	All communications with federal, state, or local agencies concerning continuity management, digital twins, or GLP-1 administration in the Twin Cities.
